The latest medical news on Myeloma
The research magnet gathers the latest research from around the web, based on your specialty area. Below you will find a sample of some of the most recent articles from reputable medical journals about myeloma gathered by our medical AI research bot.
The selection below is filtered by medical specialty. Registered users get access to the Plexa Intelligent Filtering System that personalises your dashboard to display only content that is relevant to you.
Want more personalised results?Request Access
The CAR T-cell therapy Abecma significantly extended survival in hard-to-treat relapsed or refractory myeloma patients, the KarMMa-3 trial shows.
Telo Genomics and the Mayo Clinic are developing tests to identify multiple myeloma patients at high risk of relapse following treatment.
STAR-LLD, a continuous delivery of low-dose lenalidomide, was safe and well-tolerated in healthy volunteers in a multiple myeloma trial.
A combo of teclistamab and the approved therapy Darzalex reduced the cancer burden for most relapsed or refractory myeloma patients in trial.
The very first treatment for AL amyloidosis has today been approved in Scotland. The Scottish Medicines Consortium approved the use...
The U.S. Food and Drug Administration granted orphan drug designation to Nammi Therapeutics’ QXL138AM immunotherapy for multiple myeloma.
China's regulatory agency is reviewing an application for the country's first CAR T-cell therapy for relapsed and refractory myeloma.
Talquetamab, an antibody treatment from Janssen, was granted breakthrough therapy designation by the FDA for hard-to-treat multiple myeloma.
A new analysis by Rare-X found there were at least 10,867 total rare diseases in 2021 – and shows that list is growing every year.
A European Medicines Agency branch recommended that Pepaxti (melflufen) plus dexamethasone be approved for hard-to-treat multiple myeloma.
Janssen's investigational therapy Tecvayli (teclistamab) was recommended for adults with relapsed and refractory multiple myeloma.